Pacira Pharmaceuticals

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Pacira Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#265 of 15,742 sponsors by registered trial count).

88 total trials 5 currently recruiting 65 completed top decile by trial count

Pacira Pharmaceuticals: 88 sponsored US clinical trials, 5 recruiting.

Pacira Pharmaceuticals sponsors 88 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 65 completed. 38 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteoarthritis of the Knee, with 4 trials.

Top-decile sponsor footprint

Pacira Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#265 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 38/100

65 of 82 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

88 total, page 2 of 2

COMPLETED

Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles

NCT01984619

COMPLETED NA

Effectiveness and Safety Study of the Iovera Device for the Temporary Reduction in the Appearance of Forehead Wrinkles

NCT01950065

TERMINATED Phase 4

EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries

NCT01919190

COMPLETED NA

Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device

NCT01863901

COMPLETED

A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device

NCT01801826

COMPLETED Phase 3

Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy

NCT01802411

COMPLETED

Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device

NCT01808742

COMPLETED Phase 4

Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball

NCT02142829

COMPLETED NA

Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device

NCT01753778

COMPLETED NA

Study Evaluating the Treatment of Occipital Neuralgia

NCT01753765

COMPLETED Phase 2

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

NCT01683071

COMPLETED NA

A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device

NCT01704157

COMPLETED NA

Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects

NCT01681745

COMPLETED Phase 2

Study of FX006 in Patients With Osteoarthritis of the Knee

NCT01487161

TERMINATED Phase 4

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

NCT01507233

COMPLETED Phase 4

Study of EXPAREL in Patients Undergoing Breast Augmentation

NCT01582490

COMPLETED Phase 4

EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair

NCT01801124

COMPLETED Phase 4

TAP-patients With Robotic Assisted Lap Prostatectomy

NCT01582477

COMPLETED Phase 4

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501

NCT01509638

TERMINATED Phase 4

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301

NCT01507220

COMPLETED Phase 4

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504

NCT01509807

COMPLETED Phase 4

Adult Patients Undergoing Open Colectomy MA402S23B303

NCT01507246

TERMINATED Phase 4

A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy

NCT02058290

COMPLETED Phase 2

A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines

NCT01447342

COMPLETED Phase 2

Cryo-Touch III Refinement Study Investigational Plan

NCT01379365

COMPLETED Phase 2

Cryo-Touch II for the Treatment of Wrinkles

NCT01167140

COMPLETED Phase 3

Study of Postoperative Analgesia in Bunionectomy

NCT00890682

COMPLETED Phase 1

Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation

NCT00842062

TERMINATED Phase 2

Dose Finding Posterolateral Thoracotomy Study

NCT00807209

TERMINATED Phase 3

Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation

NCT00813111

COMPLETED Phase 1

Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers

NCT00806806

COMPLETED Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty

NCT00745290

COMPLETED Phase 3

Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

NCT00744848

COMPLETED Phase 2

Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty

NCT01206608

COMPLETED Phase 2

Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy

NCT00529126

COMPLETED Phase 2

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

NCT00485693

COMPLETED Phase 2

Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair

NCT00485433

COMPLETED Phase 4

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

NCT00029523

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 22
Phase 3 17
Phase 4 21

What is open in the Pacira Pharmaceuticals pipeline

5 recruiting of 88 indexed (6% open); 65 completed (74%).

Phase mix: 38 late (III/IV) vs 35 early (I/II) (balanced across stages).

Top condition: Osteoarthritis of the Knee (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pacira Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 88 registered trials and 6% open enrollment, not the therapeutic-area sidebar.

Pacira Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 0%5%10%15%20%25% Total trials Recruiting share Pacira PharmaceuticalsAbbVie (prior sponsor, Abbott)University of Medicine and Dentistry of New JerseyAbbott NutritionFlorida International UniversityPfizerBoston CollegeCytoDynDendreon
Pacira Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pacira Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 88 trials (± recruiting share)

Sponsors near 6% open enrollment (± trial volume)

What to do with this Pacira Pharmaceuticals page

88 registered trials is a research-attention snapshot, not an endorsement of Pacira Pharmaceuticals or any single study.

  • 5 of Pacira Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Osteoarthritis of the Knee is the condition Pacira Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Osteoarthritis of the Knee trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pacira Pharmaceuticals pipeline card: 88 registered trials from official public datasets.Report a data error.